Ehsan Rahimy, MD
Retina Specialist · Stanford, CANPI 1255573606
Payments from drug & device makers
Across 1,095 payments — averaging $1368.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$819K
- Apellis Pharmaceuticals, Inc.$316K
- AbbVie$142K
- Genentech USA, Inc.$80K
- Alcon$34K
- Regeneron$33K
- plus $75K from 19 others
Across 28 payments — averaging $801.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$13K
- F. Hoffmann-la Roche AG$10K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 569 | $818,683 |
| Apellis Pharmaceuticals, Inc. | 186 | $316,037 |
| AbbVie(2 entities) | 173 | $141,681 |
| Genentech USA, Inc. | 60 | $79,662 |
| Alcon | 25 | $33,855 |
| Regeneron | 17 | $33,384 |
| Genentech, Inc. | 7 | $12,856 |
| Harrow Eye, LLC | 8 | $10,032 |
| Eyepoint US, Inc. | 9 | $8,708 |
| Carl Zeiss Meditec, Inc. | 9 | $8,442 |
| Springworks Therapeutics, Inc. | 1 | $7,985 |
| Carl Zeiss Meditec USA, Inc. | 5 | $5,472 |
| Astellas Pharma US Inc | 7 | $5,249 |
| F. Hoffmann-la Roche AG | 1 | $3,780 |
| Alcon Research LLC | 5 | $3,700 |
| Neurotech Pharmaceuticals, Inc. | 1 | $3,633 |
| Bausch & Lomb Americas Inc. | 2 | $1,797 |
| Ocular Therapeutix, Inc. | 1 | $1,500 |
| Alimera Sciences, Inc. | 2 | $1,085 |
| Dutch Ophthalmic, USA | 2 | $332 |
| Astellas Pharma Global Development | 1 | $160 |
| Biogen | 1 | $128 |
| Tarsus Pharmaceuticals, Inc. | 1 | $102 |
| Optos, Inc. | 1 | $72 |
| Novartis | 1 | $33 |
How this compares
$1,498,367 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Stanford
- Diana DoStanford$465K
- Prithvi MruthyunjayaStanford$444K
- Theodore LengStanford$308K
- Mary HartnettStanford$89K
- Charles DeboerStanford$79K
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.